Curio Wealth LLC Takes Position in Johnson & Johnson (NYSE:JNJ)

Curio Wealth LLC acquired a new stake in Johnson & Johnson (NYSE:JNJ) in the 4th quarter, Holdings Channel reports. The fund acquired 717 shares of the company’s stock, valued at approximately $104,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. IFS Advisors LLC boosted its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock valued at $25,000 after acquiring an additional 100 shares in the last quarter. Bay Harbor Wealth Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $32,000. RPg Family Wealth Advisory LLC bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $35,000. Activest Wealth Management bought a new position in shares of Johnson & Johnson during the 3rd quarter valued at about $40,000. Finally, NewSquare Capital LLC boosted its position in shares of Johnson & Johnson by 145.8% during the 4th quarter. NewSquare Capital LLC now owns 290 shares of the company’s stock valued at $42,000 after purchasing an additional 172 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research firms have recently weighed in on JNJ. Royal Bank of Canada restated an “outperform” rating and set a $181.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, February 19th. Argus upgraded Johnson & Johnson to a “strong-buy” rating in a report on Friday, January 24th. Guggenheim reiterated a “neutral” rating on shares of Johnson & Johnson in a report on Monday, March 10th. Leerink Partners decreased their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a report on Thursday, January 23rd. Finally, Morgan Stanley decreased their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 6,999 shares of the business’s stock in a transaction dated Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the transaction, the vice president now directly owns 21,001 shares of the company’s stock, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Timothy Schmid sold 403 shares of the business’s stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total transaction of $62,928.45. Following the completion of the transaction, the executive vice president now directly owns 15,098 shares of the company’s stock, valued at approximately $2,357,552.70. This represents a 2.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Company insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $162.94 on Monday. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The firm has a market capitalization of $392.29 billion, a PE ratio of 24.50, a price-to-earnings-growth ratio of 2.56 and a beta of 0.47. The firm has a 50-day moving average price of $154.98 and a 200 day moving average price of $156.27. The company has a quick ratio of 0.86, a current ratio of 1.11 and a debt-to-equity ratio of 0.43.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 earnings per share for the quarter, topping the consensus estimate of $1.99 by $0.05. The company had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company’s revenue was up 5.3% on a year-over-year basis. During the same quarter last year, the business posted $2.29 earnings per share. Research analysts anticipate that Johnson & Johnson will post 10.58 earnings per share for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th were issued a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 3.04%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.